Skip to main content
Clinical Trials/NL-OMON53341
NL-OMON53341
Not yet recruiting
Not Applicable

MUSCLE study - Mitochondrial dysfUnction: a key player in doxorubicin-induced Skeletal and Cardiac muscLE damage? - MUSCLE

niversitair Medisch Centrum Utrecht0 sites12 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Hodgkin lymphoma
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
12
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • Age \>\= 18 years
  • Patients with large B\-cell lymphoma or T\-cell lymphoma scheduled for 6
  • full\-dose cycles of 1st line immunochemotherapy with cyclophosphamide,
  • doxorubicin, vincristine and prednisone with or without rituximab ((reversed)
  • (R\-)CHOP).
  • WHO\-performance score 0\-2\.
  • Patients with sufficient Dutch writing and reading skills.
  • Written informed consent

Exclusion Criteria

  • Contra\-indications for 7T MR scanning
  • Any circumstances that would impede adherence to study requirements or
  • ability to give informed consent.
  • Medical disorders affecting mitochondrial function; e.g., spinal muscular
  • (Other) relevant medical disorders; e.g., comorbidities affecting exercise
  • Being under examination for non\-diagnosed disease at the time of
  • investigation.

Outcomes

Primary Outcomes

Not specified

Similar Trials